Overview

Safety and Antiviral Activity of Clevudine in Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials

Status:
Terminated
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine safety and efficacy of clevudine 10 mg qd for 24 weeks after completion of 24-week treatment with clevudine 30 mg qd with 12 weeks follow-up period
Phase:
Phase 3
Details
Lead Sponsor:
Bukwang Pharmaceutical
Treatments:
Antiviral Agents
Clevudine